CORDIS
EU research results

CORDIS

English EN
Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therapeutics

Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therapeutics

Objective

Colorectal cancer (CRC) is a major worldwide cancer burden with about 1.4 million cases in 2012 and an annual mortality of approximately 700,000. Early detection is crucial as treatment is most efficient in early stages where population based screenings could substantially reduce incidence and mortality.
Current screening techniques are invasive or lack sensitivity and specificity. Moreover, the molecular mechanisms leading to the formation of different antigens suggested as CRC biomarkers and potential therapeutic targets are poorly understood, especially with regard to carbohydrate-based molecules, such as glycans. Enhancing our understanding of the structure-function relationship of glycosylation in CRC could lead to the discovery of improved diagnostic and prognostic biomarkers and pave the way for nov-el therapeutic targets.
Building on an established network of analysts with many years of experience in (glyco)proteomics and biomarker research, in collaboration with colleagues in the field of glycobiology and glyco-immunology, GlyCoCan will develop new methods, and use current state of the art methods, to investigate the role of glycosylation in many different aspects of CRC.
The GlyCoCan multi-disciplinary network will principally be a training programme with a substantial industrial focus on technology transfer and teaching of internationally adopted biopharma regulations (GMP, ISO9001, ICH guidelines). The underlying specific research objectives will be addressed within individual ESR projects, giving rise to a generation of ESRs whose main focus is investigating and tackling the challenges of the role of glycosylation within CRC and other diseases.
The network will address the currently unmet need for glycosylation researchers with an inter-disciplinary perspective to fully exploit the immense potential of the young scientific field of glyco-oncology and to set them on a path to successful and productive careers in academic and industrial collaborations.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 Za Leiden

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 628 470,95

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

LUDGER LIMITED

United Kingdom

EU Contribution

€ 273 287,88

GENOS DOO ZA VJESTACENJE I ANALIZU

Croatia

EU Contribution

€ 371 641,50

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 249 216,48

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 525 751,20

STICHTING VU

Netherlands

EU Contribution

€ 255 374,28

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 258 061,32

FACULDADE DE CIENCIAS MEDICAS DA UNIVERSIDADE NOVA DE LISBOA

Portugal

NOVA ID FCT - ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT

Portugal

EU Contribution

€ 476 712,72

STICHTING VUMC

Netherlands

EU Contribution

€ 255 374,28

Partners (7)

Sort alphabetically

Expand all

Postdoc Career Development Forum BV

ROCHE DIAGNOSTICS GMBH

INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA

DC4U

UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN

MEDIZINISCHE UNIVERSITAET WIEN

Project information

Grant agreement ID: 676421

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 297 697,30

  • EU contribution

    € 3 293 890,61

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands